WILMINGTON, DEL. (CN) - MedImmune's human papillomavirus virus vaccine, Cervarix, will generate $2 billion a year and MedImmune plans to stiff the nonprofit Boyce Thompson Institute for Plant Research, which supplied it with the "high five cell line" technology that made the vaccine possible, Boyce Thompson claims in New Castle Superior Court.
MedImmune, a subsidiary of AstraZeneca, stole and converted trade secrets, in breach of contract, and plans to sell the blockbuster drug with a partner, GlaxoSmithKline, says Boyce Thompson, which seeks punitive damages. See complaint.
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.